NCT03190837 A Long-term Follow-up Study of Gaucher Disease
| NCT ID | NCT03190837 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Duke University |
| Condition | Gaucher Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2017-06-12 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2017-06-12 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims are to: a) identify the long-term natural history of Gaucher disease, b) evaluate long-term treatment efficacy of enzyme replacement therapy (ERT) and substrate reduction therapy (SRT), and c) identify potential long-term complications of this disorder. These aims will be accomplished through long-term record review of individuals with all three types of Gaucher disease.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Gaucher Disease Exclusion Criteria: * Not meeting Inclusion criteria
Contact & Investigator
Priya Kishnani, MD
PRINCIPAL INVESTIGATOR
Duke University
Frequently Asked Questions
Who can join the NCT03190837 clinical trial?
This trial is open to participants of all sexes, studying Gaucher Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03190837 currently recruiting?
Yes, NCT03190837 is actively recruiting participants. Contact the research team at janet.blount@duke.edu for enrollment information.
Where is the NCT03190837 trial being conducted?
This trial is being conducted at Durham, United States.
Who is sponsoring the NCT03190837 clinical trial?
NCT03190837 is sponsored by Duke University. The principal investigator is Priya Kishnani, MD at Duke University. The trial plans to enroll 200 participants.